Ignite Creation Date:
2024-05-06 @ 3:52 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04785326
Status:
COMPLETED
Last Update Posted:
2024-01-18
First Post:
2021-03-03
Brief Title:
Efficacy Safety and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Sponsor:
Dong-A ST Co Ltd
Organization:
Dong-A ST Co Ltd
Study Overview
Official Title:
A Randomized Double-Blind Multicentric Parallel Group Therapeutic Equivalence Study Comparing Efficacy Safety and Immunogenicity of Subcutaneous DMB-3115 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Opportuniti
Brief Summary:
This study is designed to evaluate efficacy safety pharmacokinetics PK and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None